{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:16:37Z","timestamp":1785417397795,"version":"3.56.0"},"reference-count":49,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca","award":["ES-2023-6672"],"award-info":[{"award-number":["ES-2023-6672"]}]},{"award":["ES-2023-6672"],"award-info":[{"award-number":["ES-2023-6672"]}],"id":[{"id":"https:\/\/ror.org\/05qqrnb63","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Determining homologous recombination repair (HRR) status in metastatic castration-resistant prostate cancer (mCRPC) is essential to ensure access to targeted therapies, particularly PARP inhibitors. Yet, variability in testing access and analysis performance exists. This study evaluated feasibility and outcomes of a centralized HRR testing strategy in Spain for prostate cancer patients. Methods: A total of 1412 formalin-fixed paraffin-embedded (FFPE) tumor samples from mCRPC patients from 89 Spanish institutions within a centralized multicenter molecular testing program were analyzed using a standardized 38-gene-based next-generation sequencing (NGS) assay in a central laboratory (HRR OncoKit, Health in Code, Valencia, Spain), which included five clinically relevant HRR genes: BRCA1, BRCA2, CHEK2, ATM, and CDK12. Results: HRR gene pathogenic or likely pathogenic alterations were identified in 18% (CI 95% = 16\u201320) of the patients, with BRCA2 being the most frequently altered gene (6%), followed by ATM (5%), CDK12 (4%), BRCA1 (2%), and CHEK2 (1%). Eleven percent had variants of uncertain significance. Only 13% of the samples were rejected due to poor DNA quality, low tumor content or sample age exceeding 5 years, and 2% of the samples analyzed failed since the minimum library technical quality score was not achieved. The average turnaround time for results was 18 \u00b1 3 days. Conclusions: Centralized HRR testing in mCRPC patients in Spain was feasible, efficient and reliable, identifying pathogenic alterations in 18% of the cases, similarly to the prevalence described in the literature. This testing approach facilitates precision medicine by improving the detection of actionable HRR alterations.<\/jats:p>","DOI":"10.3390\/cancers18101614","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:56:27Z","timestamp":1779094587000},"page":"1614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-252X","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Caramelo","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39008 Santander, Spain"},{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garc\u00eda-Berbel","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"},{"name":"Pathology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39009 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-2009","authenticated-orcid":false,"given":"Sofia del","family":"Carmen","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"},{"name":"Pathology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39009 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-1955","authenticated-orcid":false,"given":"Adriana","family":"Calapaqui","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"},{"name":"Pathology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39009 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Corr\u00eaa","sequence":"additional","affiliation":[{"name":"Diagnostic Data Hub-DXD Hub, 08780 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Martinez-Villase\u00f1or","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Catholic University of Valencia San Vicente M\u00e1rtir, 46001 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sotelo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39008 Santander, Spain"},{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-0290","authenticated-orcid":false,"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[{"name":"Pathology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-9435","authenticated-orcid":false,"given":"Javier","family":"G\u00f3mez-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"},{"name":"Pathology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39009 Santander, Spain"},{"name":"Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria, 39011 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-7163","authenticated-orcid":false,"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39008 Santander, Spain"},{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4168-7163","authenticated-orcid":false,"given":"Javier","family":"Freire","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla\u2014IDIVAL, 39008 Santander, Spain"},{"name":"Pathology Department, Hospital Universitario Marqu\u00e9s de Valdecilla, 39009 Santander, Spain"},{"name":"Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria, 39011 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17588359231221337","DOI":"10.1177\/17588359231221337","article-title":"Development of PARP inhibitors in advanced prostate cancer","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_6","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41391-023-00764-1","article-title":"Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: An analysis of two clinico-genomic databases","volume":"27","author":"Shui","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2020.38.6_suppl.229","article-title":"Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC)","volume":"38","author":"Shore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2023.41.6_suppl.226","article-title":"Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT","volume":"41","author":"Angel","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2024.42.4_suppl.183","article-title":"Prevalence of HRR mutations in Indian patients with mCRPC","volume":"42","author":"Batra","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00345-024-05188-7","article-title":"Real-world data on the prevalence of BRCA1\/2 and HRR gene mutations in patients with primary and metastatic castration-resistant prostate cancer","volume":"42","author":"Hommerding","year":"2024","journal-title":"World J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: A US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_24","unstructured":"National Comprehensive Cancer Network (2025). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2025, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","article-title":"Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer","volume":"7","author":"Schostak","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_27","unstructured":"National Center for Biotechnology Information (2025, January 06). ClinVar, Available online: https:\/\/www.ncbi.nlm.nih.gov\/clinvar."},{"key":"ref_28","unstructured":"Saphetor, S.A. (2025, January 06). VarSome: The Human Genomic Variant Search Engine. Available online: https:\/\/varsome.com."},{"key":"ref_29","unstructured":"Universit\u00e9 de Montpellier (2025, January 06). UMD-BRCA1 Mutations Database. Available online: http:\/\/www.umd.be\/BRCA1\/."},{"key":"ref_30","unstructured":"Universit\u00e9 de Montpellier (2025, January 06). UMD-BRCA2 Mutations Database. Available online: http:\/\/www.umd.be\/BRCA2\/."},{"key":"ref_31","unstructured":"Memorial Sloan Kettering Cancer Center (2025, January 06). OncoKB: Precision Oncology Knowledge Base. Available online: https:\/\/www.oncokb.org."},{"key":"ref_32","unstructured":"Global Alliance for Genomics and Health (2025, January 06). BRCA Exchange. Available online: https:\/\/brcaexchange.org."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"ref_35","unstructured":"National Center for Biotechnology Information (NCBI) (2025, January 12). Reference Sequence (RefSeq) Database, Available online: https:\/\/www.ncbi.nlm.nih.gov\/refseq\/."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jay, J.J., and Brouwer, C. (2016). Lollipops in the clinic: Information dense mutation plots for precision medicine. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160519"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/ijgc-2024-005756","article-title":"British Gynaecological Cancer Society\/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom","volume":"34","author":"Leung","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e2339571","DOI":"10.1001\/jamanetworkopen.2023.39571","article-title":"Rates and classification of variants of uncertain significance in hereditary disease genetic testing","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41436-018-0335-7","article-title":"Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance","volume":"21","author":"Tsai","year":"2019","journal-title":"Genet. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: Beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.annonc.2021.09.003","article-title":"Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial","volume":"32","author":"Loibl","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.2217\/fon-2021-0153","article-title":"Real-world genetic testing patterns in metastatic castration-resistant prostate cancer","volume":"17","author":"Shore","year":"2021","journal-title":"Future Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2021.39.6_suppl.49","article-title":"Genomic\/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: Results from a real-world study in the United States","volume":"39","author":"Leith","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:48:31Z","timestamp":1779425311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101614"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101614","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]}}}